Asian population, hypertensive, DBP mmHg · Asian population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
White population, normotensive, DBP mmHg · White population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
White population, hypertensive, SBP mmHg · White population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
White population, hypertensive, DBP mmHg · White population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
Black population, normotensive, SBP mmHg · Black population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
Black population, normotensive, DBP mmHg · Black population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
Black population, hypertensive, SBP mmHg · Black population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
Black population, hypertensive, DBP mmHg · Black population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
Asian population, normotensive, SBP mmHg · Asian population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
All‐cause mortality · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes all‐cause mortality compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Cardiovascular mortality · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular morbidity · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes serious adverse events compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Overall adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes overall adverse events compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes withdrawals from treatment due to adverse events compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Total mortality Duration: 1 to 5.8 years · patients with hypertension
1 finding from 1 review
Cardiovascular events · patients with hypertension
First‐line thiazides probably leads to lower total cardiovascular events Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).
1 finding from 1 review
Stroke · patients with hypertension
First‐line thiazides showed no clear difference in total stroke Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).
1 finding from 1 review
Total CHD Duration: 1 to 5 years · patients with hypertension
First‐line thiazides showed no clear difference in total CHD Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).
1 finding from 1 review
Congestive heart failure · patients with hypertension
First‐line thiazides probably leads to lower total congestive heart failure Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).
1 finding from 1 review